Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-178M | $-174M | $-157M | -96.8% | - | 39.8% |
| 2024 | $0M | $-122M | $-125M | $-101M | -90.9% | - | 29.9% |
| 2023 | $0M | $-93M | $-96M | $-96M | -75.9% | -100.0% | 11.7% |
| 2022 | $8M | $-97M | $-86M | $-101M | -40.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 179.21 |
| Research And Development | 140.32 |
| Selling General And Administration | 38.88 |
| Total Expenses | 179.21 |
| Operating Income | -179.21 |
| Total Operating Income As Reported | -179.21 |
| EBITDA | -177.57 |
| Normalized EBITDA | -171.52 |
| EBIT | -179.21 |
| Interest Income | 10.11 |
| Interest Expense | - |
| Net Interest Income | 10.11 |
| Other Non Operating Income Expenses | 0.82 |
| Other Income Expense | -5.23 |
| Interest Income Non Operating | 10.11 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 10.11 |
| Pretax Income | -174.32 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -174.32 |
| Net Income From Continuing And Discontinued Operation | -174.32 |
| Net Income From Continuing Operation Net Minority Interest | -174.32 |
| Net Income | -174.32 |
| Net Income Common Stockholders | -174.32 |
| Net Income Including Noncontrolling Interests | -174.32 |
| Normalized Income | -168.28 |
| Diluted NI Availto Com Stockholders | -174.32 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 1.64 |
| Total Unusual Items | -6.05 |
| Total Unusual Items Excluding Goodwill | -6.05 |
| Special Income Charges | - |
| Restructuring And Mergern Acquisition | - |
| Gain On Sale Of Security | -6.05 |
| General And Administrative Expense | 38.88 |
| Other Gand A | 38.88 |
| Total Other Finance Cost | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Solid Biosciences Inc.this co. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 | 5.2% | 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 |
| - |
| - |
| - |
| - |
| 8.91 |
| -14.9% |
| -46.77 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Enhabit, Inc. | EHAB | $707M | -153.68 | 1.32 | -0.9% | 20.09 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Aura Biosciences, Inc. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Peer Median | - | -12.07 | 3.02 | -24.2% | -6.95 | |